Capillary compared to venous blood sampling in clozapine treatment: patients׳ and healthcare practitioners׳ experiences with a point-of-care device
暂无分享,去创建一个
Dan Cohen | D. Cohen | Jan P. A. M. Bogers | Hong Bui | Martien Herruer | J. Bogers | H. Bui | M. Herruer
[1] Dan Cohen,et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. , 2012, The Journal of clinical psychiatry.
[2] A. Kilbourne,et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. , 2013, Psychiatric services.
[3] J. Nielsen,et al. Hematological clozapine monitoring with a point-of-care device: A randomized cross-over trial , 2012, European Neuropsychopharmacology.
[4] H. Meltzer,et al. Treatment-resistant schizophrenia--the role of clozapine. , 1997, Current medical research and opinion.
[5] M. Olfson,et al. Geographic and clinical variation in clozapine use in the United States. , 2014, Psychiatric services.
[6] J. R. van Veldhuizen,et al. FACT: A Dutch Version of ACT , 2007, Community Mental Health Journal.
[7] J. Lieberman,et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. , 1999, The American journal of psychiatry.
[8] Gerhard Nahler,et al. Committee for Proprietary Medicinal Products (CPMP) , 2009 .
[9] Shitij Kapur,et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation , 2012, British Journal of Psychiatry.
[10] H. Lublin,et al. Psychiatrists’ attitude towards and knowledge of clozapine treatment , 2010, Journal of psychopharmacology.